Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 373-377 | ISSN:2251-6727

An Integrative Model for Ayurveda-Based Drug Discovery and Development: Linking Traditional Knowledge with Molecular Validation

Dr. Chethan Kumar R[1], Dr. Nischitha M S[2], Dr. Chandrika G[3], Dr. Kavya G[3]

1.PG Scholar, Department of *Rasa Shastra & Bhaishajya Kalpana,*

JSS Ayurveda Medical College, Mysuru, India

2.Associate Professor, Department of *Rasa Shastra & Bhaishajya Kalpana*,

JSS Ayurveda Medical College, Mysuru, India

3.PG Scholar, Department of *Rasa Shastra & Bhaishajya Kalpana,*

JSS Ayurveda Medical College, Mysuru, India

3.PG Scholar, Department of *Rasa Shastra & Bhaishajya Kalpana,*

JSS Ayurveda Medical College, Mysuru, India

(Received: 27 September 2025 Revised: 05 October 2025 Accepted: 01 November 2025)

KEYWORDS

Ayurveda; Drug Discovery; Reverse Pharmacology; Target Identification; Molecular Docking; Standardization; Lead Optimization; Regulatory Science

ABSTRACT:

Drug discovery and development (DDD) represent a complex and multidisciplinary process involving the identification, optimization and clinical validation of bioactive compounds for safe and effective therapeutic use. Ayurveda, with its millennia-old pharmacopeia and holistic framework, provides a unique foundation for modern drug discovery through its systematic classification of Dravyas (substances), Gunas (properties), Karmas (actions), and Prayoga (therapeutic application).

This conceptual research article explores an integrative framework that maps classical Ayurvedic principles of Naveen Dravya Nirmana (novel formulation development) which is parallel to addition or deletion of dravyas in formulation described in Sharangadhara Samhita1 with contemporary stages of drug discovery -Target identification, Target validation, lead Identification, Lead optimization, preclinical and clinical evaluation, and regulatory validation.

Drawing from Samhitas, Nighantus, and Rasashastra treatises, the study establishes theoretical correlations between Dosha–Dhatu–Srotas interactions and modern molecular targets like genes, receptors and enzymes. Modern analytical and computational tools such as network pharmacology, molecular docking, and omics technologies are integrated within this framework.

The model emphasizes the translational potential of Ayurveda-based drug discovery through reverse pharmacology - beginning with empirical clinical evidence and moving toward experimental validation. Finally, the paper underscores the necessity of standardization, safety profiling, intellectual property rights, and global regulatory compliance to promote evidence-based Ayurvedic drug development.

1. Introduction

Drug discovery and development has traditionally been dominated by synthetic chemistry and molecular biology. However, escalating development costs, high attrition rates, and safety concerns have renewed global interest in natural product-based discovery. Ayurveda, India's ancient system of medicine, provides a rich

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 373-377 | ISSN:2251-6727

repository of biologically active materials derived from plants, minerals, and animal sources.

The principle of *Naveena Dravya Nirmana* which is parallel to addition or deletion of dravyas in formulation described in *Sharangadhara Samhita*[1] encourages the creation of new or modified formulations by applying rational logic (*Yukti*). Ayurveda's systematic framework for *Dravya*, *Guna*, *Rasa*, *Veerya*, and *Vipaka* parallels modern pharmacological concepts of physicochemical properties, mechanism of action, and metabolism.

The central thesis of this research article is that the Ayurvedic drug discovery process, when harmonized with molecular validation tools, can provide a rational, efficient and scientifically robust pathway for novel drug development.

This integration forms a foundation for developing a globally recognized and scientifically validated Ayurvedic pharmaceutics, aligning traditional *Naveena Dravya Nirmana* with modern drug discovery principles of target identification, validation, and optimization.

2. Methodology: Integrative Model for Ayurvedic Drug Discovery

The proposed conceptual framework integrates Ayurvedic epistemology with modern scientific methodology. The model parallels the classical Ayurvedic sequence of *Dravya Pariksha*, *Pramana Pariksha*, *Karma Siddhi*, and *Rogi Pariksha* with the contemporary stages of Drug Discovery and Development (DDD).

Each modern stage -**Target Identification, Target Validation, Lead Identification, Lead Optimization, Preclinical and Clinical Evaluation, and Standardization & Regulation**[2]— finds a conceptual equivalent in Ayurvedic thought.

This integrative model is built upon four primary dimensions:

1. **Philosophical Basis** – rooted in Ayurvedic understanding of *Dosha*, *Dhatu*, and *Srotas* as dynamic biological systems.

2. **Empirical Validation** – derived from centuries of clinical use documented in *Samhitas* and *Nighantus*.

3. **Experimental Correlation** – applying in vitro, in vivo, and in silico tools for target and compound validation.

4. **Regulatory Alignment** – integrating AYUSH and CDSCO standards for global credibility.

2.1 Target Identification

Classical View:

Ayurveda identifies therapeutic targets through an understanding of *Vyadhi Marga* (path of disease) and disturbances in *Dosha*, *Dhatu*, and *Srotas*. For instance, *Abhigataja Shotha* (inflammation) is caused by *Pitta–Kapha* vitiation and obstruction in *Rakta Vaha Srotas*.

Modern Correlation:

This correlates with identifying molecular targets such as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and cytokines (TNF-α, IL-6).

Integrative Strategy:

- Start with classical disease models (*Prameha*, *Shotha*, *Jwara*).
- Map to molecular pathways via bioinformatics (e.g., KEGG, STRING databases).
- Use omics technologies (genomics, proteomics, metabolomics) to identify upregulated genes and proteins.
- Validate target significance via literature and molecular docking predictions.

Example: Mapping *Prameha* (Type 2 Diabetes) → PPAR-γ and DPP-4 inhibition pathways → bioactive compounds from *Meshashringi* and *Vijaysar*.

2.2 Target Validation

Classical View:

Validation is traditionally achieved through *Pramana Pariksha* (logical and empirical evaluation) and *Karma Siddhi* (confirmation of therapeutic outcomes). Repeated successful use (*Anubandha Prayoga*) establishes therapeutic validity.

Modern Approach:

Target validation uses laboratory experiments, biomarker studies, and pharmacological assays to confirm molecular relevance.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 373-377 | ISSN:2251-6727

Integrative Model:

- Start with classical evidence like ghanas, agreya dravyas etc (*Vedanasthapaniya,jeevaniya*).
- Validate target modulation in vitro (enzyme/receptor inhibition assays).
- Confirm in vivo using animal or cell models.
- Use molecular docking to confirm ligand–target affinity.

Example:

Curcumin from *Haridra (Curcuma longa)* binds to COX-2 via hydrogen bonding, confirming its *Shothahara* (anti-inflammatory) effect both in silico and in vivo[3].

2.3 Lead Identification

Classical View:

Lead identification in Ayurveda begins from *Samhita* references and *Nighantu* classifications based on *Rasa, Guna, Veerya, Vipaka,* and *Prabhava*. These indicate pharmacological potency and therapeutic direction.

Modern Approach:

Lead identification uses extraction, isolation and screening of bioactive compounds, followed by activity testing using computational, in vitro and in vivo tools.

Integrative Strategy:

2.3.1 Select herbs with documented *Karma Siddhi* (e.g., *Guduchi*, *Tulsi*, *Haridra*).

2.3.2 Extract phytoconstituents using suitable solvents (polar, non-polar, hydroalcoholic).

2.3.3 Perform molecular docking to predict binding with identified targets.

2.3.4 Prioritize leads using ADMET and toxicity prediction.

Example:

Eugenol (from *Tulsi*) and β-caryophyllene (from *Guggulu*) show strong docking affinity toward inflammatory mediators, validating their classical *Shothahara* properties.

2.4 Lead Optimization

Classical View:

Ayurvedic pharmaceutics refines leads through *Shodhana* (purification), *Bhavana* (triturating with specific media), and *Anupana* (vehicle selection). These processes enhance potency, safety, and bioavailability.

For example, *Shodhana* of *Vatsanabha* reduces toxicity; *Ghrita Kalpana* aids lipid-soluble drug delivery; *Arishta* improves palatability and shelf life.

Modern Correlation:

Lead optimization refines molecular and pharmacokinetic characteristics using structure–activity relationship (SAR), ADME profiling, and formulation engineering.

Integration:

2.4.1 *Shodhana* → Detoxification and impurity removal.

2.4.2 *Bhavana* → Physicochemical modification to enhance absorption.

2.4.3 *Anupana* → Modern bioenhancers or carriers improving drug targeting.

2.5 Preclinical and Clinical Evaluation

Preclinical Evaluation:

In Ayurveda, preclinical evidence stems from observed effects on *Dosha* balance, *Agni*, and *Dhatu* metabolism.

Modern preclinical studies involve toxicity testing, pharmacokinetic modeling, and mechanism-based validation using animal models.

Clinical Evaluation:

Ayurveda uses *Rogi Pariksha* (patient constitution assessment) and *Vyadhi Pariksha* (disease profiling). Modern clinical research follows Good Clinical Practice (GCP) guidelines under ICMR and CDSCO.

Reverse Pharmacology Approach:

Clinical experience → Mechanistic exploration → Target validation → Standardized product development.

This approach reduces development costs and shortens timelines while maintaining clinical safety.

Journal of Chemical Health Risks
www.jchr.org
JCHR (2025) 15(5), 373-377 | ISSN:2251-6727

2.6 Standardization and Regulatory Framework

Standardization ensures the *identity, purity, potency, and safety* of formulations. Ayurveda traditionally relies on sensory and experiential validation, whereas modern science uses analytical precision.

Analytical Parameters:

- Physicochemical: pH, viscosity, particle size, moisture.
- Phytochemical: TLC, HPTLC, HPLC, GC-MS, LC-MS.
- Biological: Pharmacological activity, microbial load.

Regulatory Alignment:

- **AYUSH** – oversees ASU&H drugs.
- **CDSCO** – regulates clinical trials, safety, and efficacy.
- **WHO[4]/EMA/USFDA** – provide international compliance frameworks.

Comprehensive documentation includes toxicity data, stability studies, and pharmacovigilance reports, aligning traditional formulations with global standards.

3. Discussion

The integrative model of Ayurvedic Drug Discovery bridges *empirical tradition* with *scientific validation*. The synergy of Ayurveda and molecular biology provides multiple advantages:

1. **Reverse Pharmacology Pathway[6]:**

Begins with clinical experience → progresses toward molecular validation, optimizing time and cost.

2. **Multi-Target Efficacy:**

Ayurvedic formulations act on multiple pathways (antioxidant, anti-inflammatory, immunomodulatory).

3. **Systems Biology Harmony:**

The *Tridosha* balance aligns with modern homeostatic and network pharmacology principles.

4. **Technological Convergence:**

Docking, omics, and AI-based phytochemical screening reveal molecular mechanisms underlying Ayurvedic formulations.

5. **Innovation in Dosage Forms:**

Modern forms such as *herbo-nanoemulsions*, *transdermal patches*, and *mouthdissolving strips* enhance bioavailability and global acceptance.

6. **Quality Assurance and Ethics:**

Regulatory harmonization ensures reproducibility and safety while maintaining Ayurvedic authenticity.

Conclusion

The conceptual framework for Ayurvedic Drug Discovery and Development establishes a dynamic bridge between *traditional wisdom* and *modern science*.

By mapping Ayurvedic pharmacology (*Rasa, Guna, Veerya, Vipaka,* and *Prabhava*) to molecular pharmacology, researchers can decode classical actions into scientifically measurable mechanisms.

This integration strengthens the scientific credibility of Ayurveda and provides a systematic model for evidence-based natural drug development.

The harmonization of *Pramana Pariksha* (empirical validation) with experimental pharmacology and *Rogi Pariksha* with clinical biomarkers, paves the way for global acceptance of Ayurvedic therapeutics.

Ayurvedic pharmaceutics, when reinforced by molecular tools like docking, network pharmacology and omics-based profiling, enables identification of multi-target phytoconstituents that can combat complex diseases such as metabolic disorders, inflammation, and neurodegeneration etc.

Key Recommendations for Future Work:

1. Integrate **omics-based tools** (genomics, proteomics, metabolomics) for validating Ayurvedic pharmacological actions.
2. Apply **AI and machine learning** in phytochemical screening and docking studies to predict bioactivity.
3. Promote **reverse pharmacology** as a formal methodology for drug validation and safety profiling.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(5), 373-377 | ISSN:2251-6727

4. Enhance **standardization protocols** by combining *Dravya Pariksha* with advanced analytical tools like LC-MS and NMR.

5. Ensure **ethical and regulatory compliance** through AYUSH and international guidelines (WHO, EMA, USFDA).

6. Develop **novel dosage forms** based on Ayurvedic delivery systems (*Ghrita, Asava, Arishta*) blended with nanotechnology for targeted delivery.

Thus, the Ayurvedic model of drug discovery, when integrated with molecular validation and modern regulatory frameworks, presents an opportunity to redefine global healthcare — offering therapeutics that are safe, effective, and sustainable.

5. References

1. Sharangadhara, Purva Khanda 1/53 sharangadhara Samhita, Shri Shardharacharya Pranita,1950, Pusthakalaya, Kashi p12.
2. Gupta SK, Srivastava S. *Drug Discovery and Clinical Research.* Jaypee Brothers Medical Publishers; 2010.
3. http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84863472758&origin=inward
4. WHO. *Guidelines on Safety Monitoring of Herbal Medicines.* World Health Organization, Geneva; 2004.
5. Devyani Awari, Deorao Awari, Sagar Wankhede, Rajendra Ganjiwale, Lalit Rathi. Reverse Pharmacology: An Innovative Approach to the Study of Herbs. Research Journal of Pharmacy and Technology 2022; 15(12):5875-8. doi: 10.52711/0974-360X.2022.00991